LONDON - The charity Cancer Research UK launched a £500,000 (US$814,000) research program to use RNA interference technology to systematically uncover the function of all human genes, with the ultimate aim of identifying all genes involved in cancer that would be good drug targets. (BioWorld International)

The long-called-for restructuring of the UK biotech sector looked to have taken a major step last week when Cambridge Antibody Technology Group plc said it would acquire Oxford GlycoSciences plc in an all-share deal valuing OGS at £109.6 million (US$179.8 million). (BioWorld International)

The long-called-for restructuring of the UK biotech sector looked to have taken a major step last week when Cambridge Antibody Technology Group plc said it would acquire Oxford GlycoSciences plc in an all-share deal valuing OGS at £109.6 million (US$179.8 million). (BioWorld International)